Logo image of SPRY

ARS PHARMACEUTICALS INC (SPRY) Stock Fundamental Analysis

NASDAQ:SPRY - Nasdaq - US82835W1080 - Common Stock - Currency: USD

14.46  +0.3 (+2.12%)

After market: 14.46 0 (0%)

Fundamental Rating

5

Overall SPRY gets a fundamental rating of 5 out of 10. We evaluated SPRY against 567 industry peers in the Biotechnology industry. SPRY is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. While showing a medium growth rate, SPRY is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

SPRY had positive earnings in the past year.
In the past year SPRY had a positive cash flow from operations.
In the past 5 years SPRY reported 4 times negative net income.
SPRY had negative operating cash flow in 4 of the past 5 years.
SPRY Yearly Net Income VS EBIT VS OCF VS FCFSPRY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M

1.2 Ratios

SPRY has a Return On Assets of 2.28%. This is amongst the best in the industry. SPRY outperforms 92.24% of its industry peers.
SPRY has a Return On Equity of 3.11%. This is amongst the best in the industry. SPRY outperforms 93.12% of its industry peers.
Industry RankSector Rank
ROA 2.28%
ROE 3.11%
ROIC N/A
ROA(3y)-11.12%
ROA(5y)-13.71%
ROE(3y)-11.05%
ROE(5y)-14.05%
ROIC(3y)N/A
ROIC(5y)N/A
SPRY Yearly ROA, ROE, ROICSPRY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

SPRY has a Profit Margin of 8.97%. This is amongst the best in the industry. SPRY outperforms 93.30% of its industry peers.
Looking at the Gross Margin, with a value of 99.02%, SPRY belongs to the top of the industry, outperforming 97.71% of the companies in the same industry.
Industry RankSector Rank
OM N/A
PM (TTM) 8.97%
GM 99.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SPRY Yearly Profit, Operating, Gross MarginsSPRY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K -200K

More info and screens

8

2. Health

2.1 Basic Checks

SPRY does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SPRY has been increased compared to 1 year ago.
SPRY has more shares outstanding than it did 5 years ago.
SPRY has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SPRY Yearly Shares OutstandingSPRY Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
SPRY Yearly Total Debt VS Total AssetsSPRY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 9.83 indicates that SPRY is not in any danger for bankruptcy at the moment.
The Altman-Z score of SPRY (9.83) is better than 87.48% of its industry peers.
There is no outstanding debt for SPRY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 9.83
ROIC/WACCN/A
WACC10.04%
SPRY Yearly LT Debt VS Equity VS FCFSPRY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 14.26 indicates that SPRY has no problem at all paying its short term obligations.
The Current ratio of SPRY (14.26) is better than 89.07% of its industry peers.
A Quick Ratio of 14.04 indicates that SPRY has no problem at all paying its short term obligations.
The Quick ratio of SPRY (14.04) is better than 88.54% of its industry peers.
Industry RankSector Rank
Current Ratio 14.26
Quick Ratio 14.04
SPRY Yearly Current Assets VS Current LiabilitesSPRY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

5

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 108.77% over the past year.
Looking at the last year, SPRY shows a very strong growth in Revenue. The Revenue has grown by 297063.33%.
EPS 1Y (TTM)108.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%800%
Revenue 1Y (TTM)297063.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SPRY will show a very strong growth in Earnings Per Share. The EPS will grow by 88.12% on average per year.
Based on estimates for the next years, SPRY will show a very strong growth in Revenue. The Revenue will grow by 104.65% on average per year.
EPS Next Y-2867.61%
EPS Next 2Y-267.31%
EPS Next 3Y69.33%
EPS Next 5Y88.12%
Revenue Next Year380.02%
Revenue Next 2Y240.61%
Revenue Next 3Y163.51%
Revenue Next 5Y104.65%

3.3 Evolution

SPRY Yearly Revenue VS EstimatesSPRY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
SPRY Yearly EPS VS EstimatesSPRY Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 289.20, the valuation of SPRY can be described as expensive.
91.89% of the companies in the same industry are more expensive than SPRY, based on the Price/Earnings ratio.
SPRY's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.22.
The Forward Price/Earnings Ratio is negative for SPRY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 289.2
Fwd PE N/A
SPRY Price Earnings VS Forward Price EarningsSPRY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 100 150 200 250

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, SPRY is valued cheaply inside the industry as 93.12% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 109.37
EV/EBITDA N/A
SPRY Per share dataSPRY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

SPRY's earnings are expected to grow with 69.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-267.31%
EPS Next 3Y69.33%

More info and screens

0

5. Dividend

5.1 Amount

SPRY does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARS PHARMACEUTICALS INC

NASDAQ:SPRY (5/2/2025, 8:24:02 PM)

After market: 14.46 0 (0%)

14.46

+0.3 (+2.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-20 2025-03-20/bmo
Earnings (Next)05-19 2025-05-19/bmo
Inst Owners66.89%
Inst Owner ChangeN/A
Ins Owners18.28%
Ins Owner Change-0.76%
Market Cap1.42B
Analysts88.33
Price Target32.23 (122.89%)
Short Float %24.51%
Short Ratio9.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)205.1%
Min EPS beat(2)-32.93%
Max EPS beat(2)443.14%
EPS beat(4)2
Avg EPS beat(4)100.73%
Min EPS beat(4)-32.93%
Max EPS beat(4)443.14%
EPS beat(8)5
Avg EPS beat(8)59.11%
EPS beat(12)6
Avg EPS beat(12)89.66%
EPS beat(16)8
Avg EPS beat(16)63.12%
Revenue beat(2)2
Avg Revenue beat(2)344.62%
Min Revenue beat(2)252.6%
Max Revenue beat(2)436.64%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.77%
PT rev (3m)5.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-89.96%
EPS NY rev (1m)-24.24%
EPS NY rev (3m)-284.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-48.86%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-26.95%
Valuation
Industry RankSector Rank
PE 289.2
Fwd PE N/A
P/S 15.93
P/FCF 109.37
P/OCF 104.82
P/B 5.53
P/tB 5.69
EV/EBITDA N/A
EPS(TTM)0.05
EY0.35%
EPS(NY)-1.38
Fwd EYN/A
FCF(TTM)0.13
FCFY0.91%
OCF(TTM)0.14
OCFY0.95%
SpS0.91
BVpS2.61
TBVpS2.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.28%
ROE 3.11%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 8.97%
GM 99.02%
FCFM 14.57%
ROA(3y)-11.12%
ROA(5y)-13.71%
ROE(3y)-11.05%
ROE(5y)-14.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score7
Asset Turnover0.25
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 712.66%
Cap/Sales 0.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 162.35%
Current Ratio 14.26
Quick Ratio 14.04
Altman-Z 9.83
F-Score7
WACC10.04%
ROIC/WACCN/A
Cap/Depr(3y)338.3%
Cap/Depr(5y)266.86%
Cap/Sales(3y)199.71%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)108.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%800%
EPS Next Y-2867.61%
EPS Next 2Y-267.31%
EPS Next 3Y69.33%
EPS Next 5Y88.12%
Revenue 1Y (TTM)297063.33%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year380.02%
Revenue Next 2Y240.61%
Revenue Next 3Y163.51%
Revenue Next 5Y104.65%
EBIT growth 1Y95.43%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-119.75%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y121.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y122.86%
OCF growth 3YN/A
OCF growth 5YN/A